XSpray Pharma AB Cash Flow-to-Debt Ratio
XSpray Pharma AB cash flow-to-debt ratio. XSpray Pharma AB (XSPRAY) has a Cash Flow-to-Debt Ratio of -0.21x as of June 2026, meaning its operating cash flow of Skr-36.95 Million could theoretically repay 0% of its total liabilities (Skr173.68 Million) in one year. Check cash flow quality index of XSpray Pharma AB to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of XSpray Pharma AB (2015–2025)
Cash flow-to-debt ratio of XSpray Pharma AB from 2015 to 2025. Historical debt coverage capacity for XSpray Pharma AB across 11 annual periods. Check XSpray Pharma AB cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
XSpray Pharma AB Cash Flow-to-Debt Ratio by Year (2015–2025)
XSpray Pharma AB cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for XSpray Pharma AB. For the full cash flow conversion analysis, see cash flow conversion of XSpray Pharma AB.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.17x | Skr-193.16 Million | Skr164.70 Million | ▲ +8.6% |
| 2024 | -1.28x | Skr-222.37 Million | Skr173.25 Million | ▲ +54.6% |
| 2023 | -2.83x | Skr-203.28 Million | Skr71.85 Million | ▲ +24.5% |
| 2022 | -3.75x | Skr-110.18 Million | Skr29.41 Million | ▼ -126.1% |
| 2021 | -1.66x | Skr-51.61 Million | Skr31.15 Million | ▲ +21.3% |
| 2020 | -2.10x | Skr-47.79 Million | Skr22.72 Million | ▼ -65.7% |
| 2019 | -1.27x | Skr-34.24 Million | Skr26.96 Million | ▲ +22.9% |
| 2018 | -1.65x | Skr-17.75 Million | Skr10.77 Million | ▲ +14.1% |
| 2017 | -1.92x | Skr-11.04 Million | Skr5.75 Million | ▼ -492.8% |
| 2016 | -0.32x | Skr-1.74 Million | Skr5.39 Million | ▲ +93.3% |
| 2015 | -4.82x | Skr-12.96 Million | Skr2.69 Million | — |